- In April 2024, Revvity (U.S.) launched the Auto-Pure 2400 liquid handler, developed by Allsheng, for use with the T-SPOT.TB test. This platform enables laboratories to streamline workflows, allowing latent TB testing to be conducted efficiently in mid-to-high-volume settings
- In March 2024, QIAGEN (Netherlands) partnered with the International Panel Physicians Association (IPPA) to support and educate panel physicians worldwide on the latest tuberculosis (TB) screening requirements. This collaboration emphasized the Interferon Gamma Release Assay (IGRA) requirements and their benefits for both patients and healthcare providers
- In February 2023, QIAGEN's (Netherlands) QuantiFERON-TB Gold Plus, a leading TB blood test, received the CE Mark under the European Union's 2017/746 In Vitro Diagnostic Medical Devices Regulation (IVDR). This certification replaced the earlier 98/79/EC In Vitro Diagnostic Directive (IVDD), ensuring compliance with more stringent regulatory standards for in vitro diagnostic devices
- In December 2022, bioMérieux (France) announced the CE-marking of VIDAS KUBE, a next-generation automated immunoassay system within the VIDAS assay range. This system includes the VIDAS TB-IGRA test for latent TB, offering significant benefits to clinical laboratories by delivering faster results, enhancing patient care, and ensuring consumer protection
